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D

espite a national campaign to
promote early ambulation, sequential
compression devices, and chemoprophylaxis, venous thromboembolic events
(VTE), including deep venous thromboses and
pulmonary emboli, pose a significant burden to
most hospitalized patients, especially with poor
mobility. As such, many surgical specialties have
published randomized clinical trials to establish
best practices in prophylactic unfractionated
heparin (UFH) vs low-molecular-weight heparin
(LMWH).1-3 Unfortunately, neurosurgery for
a myriad of reasons has been slow to adapt,
although chemoprophylactic techniques are
implemented in most, if not all, of our patients.
Interest in comparing the two subcutaneous
injections was recently revived with a metaanalysis in neurosurgical procedures4 followed
by a survey for spine operations.5 The authors
should be congratulated for publishing their
findings, “Comparison of the safety of prophylactic anticoagulants after intracranial surgery.”6
The study presents a propensity score matching
of prophylactic anticoagulants after intracranial
surgery.
The authors have remarkably paired 203
cranial surgery patients with LMWH to 406
patients with UFH in a 1:2 ratio. The propensity
score algorithm allows for assigning patients
who may not have an exact matching double.
This addresses the difficulty in traditional
matched cohort studies that often restricts
the study population size7 – a difficulty that
we encountered in our similarly paired study
in chemoprophylaxis with spinal applications (currently in production). The author’s
matched data unveiled a statistically significantly
higher incidence of intracranial hemorrhagic
complications with LMWH without a benefit
in prevention of VTE. These results echo
one of the first reports of LMWH in cranial
surgery: in 1998, Dickinson et al8 randomized
LMWH + sequential compression device to
sequential compression device alone in patients

requiring surgery for treatment of intracranial
neoplasms. The study was terminated prematurely because of the 10% rate of intracranial
hemorrhage in the LMWH cohort vs none
in the sequential compression device alone
cohort. While neurosurgeons were understandably suspicious of LMWH as a result of
this study, an important counterargument did
beg the question: Was the increased risk of
intracranial hemorrhage unique to LMWH or a
phenomenon true to any comparison cohort of
chemoprophylaxis vs no pharmacological anticoagulant? Over 2 decades later, the authors of the
current study have attempted a more modern
approach with a more statistically nuanced
analysis. The former scenario seems to hold
true. Hemorrhagic complications are unique to
LMWH itself. The smaller molecular structure
of LMWH compared to UFH confers higher
anti-Xa/anti-IIa ratios.9 These biochemical
properties permit nonspecific binding to body
proteins and cell surfaces of the coagulation
cascade (such as endothelia and platelets), which
explains LMWH’s greater efficacy against VTE
as well as complication profile with intracranial
hemorrhages.
As with any retrospective study, there are
important potential confounders and hidden
bias to consider when interpreting these findings.
While propensity matching can help modulate
the effect of potential confounders, this is
dependent on the factors that are considered
in the model. One of the biggest limitations of this study is that many factors that
may be associated with the primary outcomes
are not considered. Specific morbidities related
to frailty as well as propensity to hemorrhage are not collected within the examined
data set. Additionally, both the retrospective
cohort arm as well as the meta-analysis are
subject to a calendar time bias. Earlier operations may have utilized postoperative prophylactic UFH, whereas more recent operations may
have preferred prophylactic LMWH. This poses
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several problems. On one hand, newer developments in intraoperative hemostatic agents made a profound impact on the
prevention of intracranial hemorrhage.10 This would suggest
that when controlling for these hemostatic agents, hemorrhagic
complications would be even higher in the LMWH group.
On the other hand, however, there may be potential bias
based on the aggressiveness and extent of resection, especially
in the more modern cases in this series which may increase
the risk of intracranial hemorrhage. These operative nuances
that affect the rates of intracranial hemorrhage were unlikely
to be captured in the propensity score matching on “surgical
procedure.” Moreover, higher resolution in postoperative imaging
modalities over the years may identify subtle hemorrhages in the
more recent LMWH cohort compared to the earlier UFH cohort.
The authors also failed to mention preoperative antithrombotic
agents, which undoubtedly alter hemorrhage rates. As the number
of patients with chronic medical conditions rises, more patients
are taking antithrombotic drugs than in previous years.11 And
while Coumadin (Bristol Myers Squibb) prescriptions have fallen,
the number of novel oral anticoagulants whose safety profile with
intracranial hemorrhages has not been completely determined has
increased.12 In summary, the higher incidence of hemorrhagic
complications may reflect a change in the landscape of medical
and surgical practice, rather than a change from postoperative
prophylactic UFH to LMWH over the past decades.
While this retrospective analysis is helpful, chemoprophylactic
efficacy truly presides in a randomized clinical trial that would
compare weight-based dosing in LMWH vs UFH in a select
group of neurosurgical operations. But, as noted in the author’s
meta-analysis, the small difference in VTE between LMWH and
UFH would require an impractically sized study population to
adequately power such a randomized clinical trial. A large-scale
study would entail a multi-center design with funding, which
poses its own difficulties. Pharmaceutical companies may be
apprehensive to support such a trial that may conclude that their
drug was inferior to traditional UFH, or neurosurgeons may not
trust studies fraught in monetary conflicts of interest with big
pharma. In the end, our choice in chemoprophylactic technique
may depend on the current body of evidence in the literature
mixed with anecdotal experience unique to our individualized
neurosurgical practice.

